4-(2-(2,6-dichlorophenyl)-1H-imidazol-5-yl)pyridine | 1454838-73-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-(2-(2,6-dichlorophenyl)-1H-imidazol-5-yl)pyridine
• 英文别名: 4-[2-(2,6-dichlorophenyl)-1H-imidazol-5-yl]pyridine
• CAS: 1454838-73-3
• 化学式: C₁₄H₉Cl₂N₃
• 分子量: 290.152
• InChiKey: RWGMSQLDRQDCDW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2-溴-1-吡啶-4-基乙酮 、 2,6-二氯苯甲酰胺盐酸盐 在 sodium carbonate 作用下， 以 1,4-二氧六环 为溶剂， 反应 48.0h， 生成 4-(2-(2,6-dichlorophenyl)-1H-imidazol-5-yl)pyridine
  参考文献：
  名称：

  Lead identification of novel and selective TYK2 inhibitors

  摘要：

  A therapeutic rationale is proposed for the treatment of inflammatory diseases, such as psoriasis and inflammatory bowel diseases (IBD), by selective targeting of TYK2. Hit triage, following a high-throughput screen for TYK2 inhibitors, revealed pyridine I as a promising starting point for lead identification. Initial expansion of 3 separate regions of the molecule led to eventual identification of cyclopropyl amide 46, a potent lead analog with good kinase selectivity, physicochemical properties, and pharmacokinetic profile. Analysis of the binding modes of the series in TYK2 and JAK2 crystal structures revealed key interactions leading to good TYK2 potency and design options for future optimization of selectivity. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.03.070

文献信息

• Lead identification of novel and selective TYK2 inhibitors
  作者：Jun Liang、Vickie Tsui、Anne Van Abbema、Liang Bao、Kathy Barrett、Maureen Beresini、Leo Berezhkovskiy、Wade S. Blair、Christine Chang、James Driscoll、Charles Eigenbrot、Nico Ghilardi、Paul Gibbons、Jason Halladay、Adam Johnson、Pawan Bir Kohli、Yingjie Lai、Marya Liimatta、Priscilla Mantik、Kapil Menghrajani、Jeremy Murray、Amy Sambrone、Yisong Xiao、Steven Shia、Young Shin、Jan Smith、Sue Sohn、Mark Stanley、Mark Ultsch、Birong Zhang、Lawren C. Wu、Steven Magnuson

  DOI：10.1016/j.ejmech.2013.03.070

  日期：2013.9

  A therapeutic rationale is proposed for the treatment of inflammatory diseases, such as psoriasis and inflammatory bowel diseases (IBD), by selective targeting of TYK2. Hit triage, following a high-throughput screen for TYK2 inhibitors, revealed pyridine I as a promising starting point for lead identification. Initial expansion of 3 separate regions of the molecule led to eventual identification of cyclopropyl amide 46, a potent lead analog with good kinase selectivity, physicochemical properties, and pharmacokinetic profile. Analysis of the binding modes of the series in TYK2 and JAK2 crystal structures revealed key interactions leading to good TYK2 potency and design options for future optimization of selectivity. (C) 2013 Elsevier Masson SAS. All rights reserved.